FDAnews
www.fdanews.com/articles/213000-illumina-prepares-for-grail-divestiture

Illumina Prepares for Grail Divestiture

December 18, 2023

Illumina announced that it has filed a draft notice to the Securities and Exchange Commission related to its potential divestiture of Grail, pursuant to an order Illumina received from the European Commission (EC) directing the company to divest Grail.

In a statement, Illumina said that “submission of this registration statement is an important next step in evaluating divestiture options for Grail,” and that “under the terms of the EC’s order, Illumina is permitted to explore a range of structures including, but not limited to, a third-party sale.”

Illumina is still waiting for decisions on its appeals from the European Court of Justice and the U.S. Fifth Circuit Court of Appeals. If the company is not successful with either of its appeals, Illumina will divest Grail, the company said.

To read the whole story, click here to subscribe.

Related Topics